Vander Borght T, Laloux P, Maes A, Salmon E, Goethals I, Goldman S
Nuclear Medicine Division, Mont-Godinne Medical Center, Université Catholique de Louvain, B-5530 Yvoir, Belgium.
Acta Neurol Belg. 2001 Dec;101(4):196-209.
The purpose of these guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion SPECT studies using Tc-99m radiopharmaceuticals and brain metabolism PET studies using F-18 fluorodeoxyglucose (FDG). These guidelines have been adapted and extended from those produced by the Society of Nuclear Medicine (Juni et al., 1998) and the European Association of Nuclear Medicine by a Belgian group of experts in the field trained in neurology and/or nuclear medicine. Some indications are not universally approved (e.g. brain death), but largely supported by the literature. They have been included in these guidelines in order to provide recommendations and a standardised protocol.
这些指南的目的是协助核医学从业者推荐、进行、解读和报告使用锝-99m放射性药物的脑灌注单光子发射计算机断层扫描(SPECT)研究以及使用氟-18氟脱氧葡萄糖(FDG)的脑代谢正电子发射断层扫描(PET)研究的结果。这些指南是对比利时一组在神经病学和/或核医学领域接受培训的专家对核医学协会(Juni等人,1998年)和欧洲核医学协会制定的指南进行改编和扩展而来的。一些适应症并非得到普遍认可(例如脑死亡),但在很大程度上得到了文献的支持。它们被纳入这些指南是为了提供建议和标准化方案。